PLYMOUTH, Minn., Dec. 15, 2009 (GLOBE NEWSWIRE) -- ev3 Inc. (Nasdaq:EVVV) today announced the promotion of two executives effective January 1, 2010. Pascal E.R. Girin has been promoted to the newly created position of executive vice president and chief operating officer, and David Mowry has been promoted to senior vice president and president, worldwide neurovascular.
Robert Palmisano, president and chief executive officer of ev3 Inc., commented, "I'm delighted to announce both of these promotions. Throughout the past six years, Pascal has been a major contributor to the company's growth and success, including the expansion of our international operations and our worldwide neurovascular business to the #2 overall revenue share position. Dave has done an outstanding job of leading our global operations, where he has been instrumental in raising margins, improving manufacturing efficiencies and enhancing our business processes. I'm confident that these promotions will further bolster our ability to capitalize on the growth opportunities within our neurovascular, peripheral vascular and international businesses and to accelerate their market performance."
As chief operating officer, Girin will have global operating responsibility for ev3's peripheral vascular, neurovascular and international businesses. Girin has served as ev3's executive vice president and president, worldwide neurovascular and international since July 2008. Prior to this, Girin served as senior vice president and president of international from August 2007 to July 2008; president of international from July 2005 to August 2007 and European general manager from September 2003 to July 2005. Prior to joining ev3, Girin served in various capacities at BioScience Europe Baxter Healthcare Corporation from September 1998 to August 2003. Girin received an Engineering Education at the French Ecole des Mines.
In his new role, Mowry will have global responsibility for ev3's neurovascular business. Mowry has served as ev3's senior vice president, strategy and corporate operations since July 2008. Prior to this, he served as senior vice president, corporate manufacturing from October 2007 to July 2008 and vice president of operations from November 2006 to October 2007. Prior to ev3, Mowry served as the vice president of operations and logistics at the Zimmer-Spine division of the Zimmer Corporation from February 2004 to November 2006. Prior to Zimmer, he was the president and chief operating officer of Heartstent. Mowry is a graduate of the United States Military Academy in West Point, New York with a degree in Engineering and Mathematics.
About ev3 Inc.
Since its founding in 2000, ev3 has been dedicated to developing breakthrough and clinically proven technologies for the endovascular treatment of peripheral vascular and neurovascular diseases. The company offers a comprehensive portfolio of treatment options, including the primary interventional technologies used today - peripheral angioplasty balloons, stents, plaque excision systems, embolic protection devices, liquid embolics, embolization coils, flow diversion devices, thrombectomy catheters and occlusion balloons. More information about the company and its products can be found at www.ev3.net.
ev3 and the ev3 logo are trademarks of ev3 Inc., registered in the U.S. and other countries.
Forward-Looking Statements
Statements contained in this press release that relate to future, not past, events are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Forward-looking statements often can be identified by words such as "expect," "anticipate," "intend," "will," "may," "believe," "could," "continue," "future," "estimate," "outlook," "guidance," or the negative of these words or other words of similar meaning. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause ev3's actual results to be materially different than those expressed in or implied by ev3's forward-looking statements. For ev3, particular uncertainties and risks include, among others, ev3's future operating results and financial performance, fluctuations in foreign currency exchange rates, the effect of the current global economic crisis, ev3's ability to implement, fund and achieve sustainable cost savings measures that will better align its operating expenses with its anticipated net sales levels and reallocate resources to better support growth initiatives, the timing of regulatory approvals and introduction of new products, market acceptance of new products, success of clinical testing, availability of third party reimbursement, impact of competitive products and pricing, the effect of regulatory actions and the cost and effect of changes in tax and other legislation. More detailed information on these and additional factors that could affect ev3's actual results are described in ev3's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. Except as required by law, ev3 undertakes no obligation to publicly update its forward-looking statements.